Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.45 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | CTSG | P08311 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21595440 | 0.92 | ELANE (0.44) | ELANEF2CTSG | |
| SCHEMBL21595452 | 0.82 | ELANE (0.43) | ELANEF2CTSG | |
| SCHEMBL21595437 | 0.80 | FAAH (0.37) | — | |
| SCHEMBL30832481 | 0.78 | MEN1 (0.50) | — | |
| SCHEMBL21595372 | 0.78 | GRIN2B (0.39) | — | |
| SCHEMBL7606324 | 0.77 | MEN1 (0.49) | — | |
| SCHEMBL21595431 | 0.76 | NPC1 (0.46) | — | |
| SCHEMBL24221032 | 0.75 | MEN1 (0.53) | — | |
| SCHEMBL18712918 | 0.73 | RET (0.48) | — | |
| SCHEMBL7522381 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-11274111-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME CORP. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3810615-A1 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019245890-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | ELANE 121/4885F2 1422/4885CTSG 494/4885 |
| US-11274111-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | ELANE 121/4885F2 1422/4885CTSG 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.